导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.63% | 3609/4773 |
| 近一周 | -3.27% | 3979/5462 |
| 近一月 | -9.32% | 4674/5421 |
| 近一季 | -5.18% | 1781/5209 |
| 近半年 | -11.75% | 3742/4920 |
| 近一年 | -11.98% | 3532/4366 |
| 近两年 | 58.00% | 1265/2954 |
| 近三年 | 9.11% | 1765/2253 |
| 成立以来 | -15.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.58% 3652/4961 |
11.01% 2376/5312 |
- - |
- - |
| 2025 | 13.08% 2660/4813 |
4.92% 861/3635 |
-2.05% 3300/4076 |
22.45% 1651/4524 |
-10.14% 4138/4813 |
| 2024 | 9.60% 1459/3463 |
-5.98% 1984/2808 |
-11.64% 2556/3014 |
18.55% 989/3129 |
11.28% 224/3463 |
| 2023 | -1.73% 530/2656 |
34.48% 57/2280 |
-8.98% 2025/2385 |
-14.97% 2205/2515 |
-5.57% 1402/2655 |
| 2022 | -25.81% 1347/2207 |
-21.22% 1608/1919 |
-2.66% 1786/2016 |
-14.21% 1047/2113 |
12.77% 121/2208 |
| 2021 | -1.16% 785/1822 |
-6.51% 1011/1255 |
11.44% 375/1330 |
-8.60% 1144/1466 |
3.79% 390/1822 |
| 2020 | 20.49% 714/1250 |
4.37% 75/1028 |
16.36% 444/1067 |
-0.38% 1054/1164 |
-0.40% 1074/1184 |
| 2019 | 48.34% 114/1092 |
47.00% 11/739 |
-9.20% 640/788 |
6.53% 121/850 |
4.32% 810/918 |
| 2018 | -25.22% 342/834 |
- - |
-15.44% 520/631 |
-7.39% 450/660 |
-13.43% 535/682 |
| 2017 | -2.20% 500/714 |
- - |
- - |
- - |
- - |
| 2016 | -32.47% 511/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证计算机ETF联接C VS. 长安沪深300非周期A(740101) |